Update on statin-mediated anti-inflammatory activities in atherosclerosis

被引:84
作者
Montecucco, Fabrizio [1 ]
Mach, Francois [1 ]
机构
[1] Univ Hosp Geneva, Div Cardiol, Dept Med, Fdn Med Res, CH-1211 Geneva, Switzerland
基金
瑞士国家科学基金会;
关键词
Statin; Atherosclerosis; Inflammation; Kinases; Cholesterol; HMG-COA REDUCTASE; C-REACTIVE PROTEIN; COENZYME-A REDUCTASE; ENDOTHELIAL PROGENITOR CELLS; HIGH CARDIOVASCULAR RISK; NITRIC-OXIDE SYNTHASE; ACUTE CORONARY SYNDROMES; LOW-DENSITY-LIPOPROTEIN; FACTOR-KAPPA-B; FLUVASTATIN INDUCES APOPTOSIS;
D O I
10.1007/s00281-009-0150-y
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anti-inflammatory activities of statins in atherosclerosis have been well documented by both basic research and clinical studies. Statins have been introduced in the 1980s as 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to block cholesterol synthesis and lower cholesterol serum levels. In the last three decades, statins have been shown to possess several anti-inflammatory and antioxidant activities resulting in the beneficial reduction of atherosclerotic processes and cardiovascular risk in both humans and animal models. Inflammatory intracellular pathways involving kinase phosphorylation and protein prenylation are modulated by statins. The same intracellular mechanisms might also cause statin-induced myotoxicity. In the present review, we will update evidence on statin-mediated regulation of inflammatory pathways in atherogenesis.
引用
收藏
页码:127 / 142
页数:16
相关论文
共 217 条
[1]   Pravastatin prevents myocardium from ischemia-induced fibrosis by protecting vascular endothelial cells exposed to oxidative stress [J].
Abe, Yuichi ;
Izumi, Takehiko ;
Urabe, Akihiro ;
Nagai, Makoto ;
Taniguchi, Ikuo ;
Ikewaki, Katsunori ;
Mochizuki, Seibu .
CARDIOVASCULAR DRUGS AND THERAPY, 2006, 20 (04) :273-280
[2]  
*AM HEART ASS, 2002, 2002 HEART STROK STA
[3]   Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives [J].
Anderssen, SA ;
Hjelstuen, AK ;
Hjermann, I ;
Bjerkan, K ;
Holme, I .
ATHEROSCLEROSIS, 2005, 178 (02) :387-397
[4]  
[Anonymous], 2002, JAMA, V288, P2998
[5]  
Arca M, 2007, DRUGS, V67, P43, DOI 10.2165/00003495-200767001-00005
[6]   Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events [J].
Arca, Marcello ;
Gaspardone, Achille .
DRUGS, 2007, 67 (Suppl 1) :29-42
[7]   Toward immunomodulatory and anti-inflammatory properties of statins [J].
Arnaud, C ;
Braunersreuther, V ;
Mach, F .
TRENDS IN CARDIOVASCULAR MEDICINE, 2005, 15 (06) :202-206
[8]   Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes - New evidence for direct antiinflammatory effects of statins [J].
Arnaud, C ;
Burger, F ;
Steffens, S ;
Veillard, NR ;
Nguyen, TH ;
Trono, D ;
Mach, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (06) :1231-1236
[9]   Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells [J].
Arora, Meenakshi ;
Chen, Li ;
Paglia, Melissa ;
Gallagher, Iain ;
Allen, Judith E. ;
Vyas, Yatin M. ;
Ray, Anuradha ;
Ray, Prabir .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (20) :7777-7782
[10]   HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes [J].
Assmus, B ;
Urbich, C ;
Aicher, A ;
Hofmann, WK ;
Haendeler, J ;
Rössig, L ;
Spyridopoulos, I ;
Zeiher, AM ;
Dimmeler, S .
CIRCULATION RESEARCH, 2003, 92 (09) :1049-1055